Welcome to our dedicated page for Senseonics Holdings news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.
Senseonics Holdings, Inc. (symbol: SENS) is a pioneering medical technology firm based in Germantown, Maryland. The company's primary focus is on developing and commercializing advanced glucose monitoring systems that significantly improve the lives of people managing diabetes. Utilizing cutting-edge fluorescence sensing technology, Senseonics has designed the Eversense Continuous Glucose Monitoring (CGM) System, recognized for being the first fully implantable CGM system. This system comprises a tiny sensor implanted under the skin, an external smart transmitter, and a user-friendly mobile application, allowing for real-time glucose monitoring without the need for a dedicated receiver.
The Eversense CGM System stands out for its accuracy and stability throughout its extended sensor life, offering continuous glucose monitoring for up to 180 days. This long-term solution provides an alternative to traditional short-term CGMs, catering to individuals who require a more stable and reliable glucose monitoring option.
Senseonics has established strong partnerships, including a notable collaboration with Ascensia Diabetes Care, which ensures that their innovative solutions reach a global audience. Their latest product, the Eversense E3 CGM System, is part of an extended assistance program known as the Eversense Payment Assistance and Simple Savings (PASS) Program. This program offers eligible individuals in the U.S. the opportunity to access the Eversense E3 systems at a significantly reduced out-of-pocket cost of $99 for each six-month period, thereby making continuous glucose monitoring more affordable.
Senseonics is committed to advancing diabetes management technology, as evidenced by their continued innovation and dedication to improving accessibility to their products. The company's forward-looking approach and strategic alliances position them as a key player in the medical technology landscape, specifically in the context of diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) reported a revenue of $3.7 million for Q2 2022, up from $3.3 million in Q2 2021. The U.S. revenue increased to $1.2 million from $1.0 million year-over-year. Gross profit improved to $0.8 million, up from $0.4 million. Notably, the company recorded a net income of $104.2 million, attributed to adjustments in embedded derivatives. Senseonics also reaffirmed its full-year revenue guidance of $14.0 million to $18.0 million. Recent highlights included CE mark approval for the E3 system and improved patient access through coverage decisions.
Senseonics Holdings, Inc. (AMEX: SENS) announced that Anthem is providing coverage for its Eversense E3 Continuous Glucose Monitoring (CGM) System, adding over 45 million covered lives. This expands the total coverage for Eversense to approximately 250 million lives in the U.S. The Eversense CGM offers a six-month sensor life, accurate glucose data, and remote monitoring capabilities for diabetes management. The decision follows similar coverage expansions by other major insurers, enhancing the accessibility of this advanced monitoring technology.
Senseonics Holdings, Inc. (NYSE American: SENS) announced plans to release its Q2 2022 financial results on August 9, 2022, after market close. Management will review the performance during a conference call at 4:30 p.m. (ET), which will be available via a webcast on the company's website. Senseonics specializes in long-term implantable continuous glucose monitoring (CGM)
Senseonics Holdings, Inc. (NYSE American: SENS) announced equity grants to 17 new non-executive employees under its 2019 Inducement Plan. Each employee received non-qualified stock options to purchase 199,000 shares at an exercise price of $1.02 per share, corresponding to the closing price on July 1, 2022. The options will vest over four years, contingent on continued employment. Senseonics aims to expand its Eversense Continuous Glucose Monitoring (CGM) System for diabetes management globally.
Senseonics Holdings, Inc. has received CE Mark approval for the Eversense® E3 CGM System, allowing commercialization in select European markets. The E3 system is the longest-lasting continuous glucose monitoring device, with a wear duration of up to 6 months and superior accuracy. Ascensia Diabetes Care, Senseonics’ commercial partner, will launch the product in Germany, Italy, Spain, and other EU countries starting Q3 2022. The E3 system enhances operational efficiency and supports non-adjunctive use, improving treatment decisions without confirmatory fingerstick tests.
Senseonics Holdings, Inc. (AMEX: SENS) announced its participation in the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022, at 1:30pm ET. The presentation will be accessible via a live and recorded webcast on the company's website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, including Eversense® devices, designed to aid diabetes management. The company aims to transform lives by providing innovative glucose monitoring solutions.
Senseonics Holdings, Inc. (AMEX: SENS) has announced its participation in the hybrid H.C. Wainwright Global Investment Conference on May 24, 2022. Management will engage in virtual one-on-one meetings, with a webcast presentation starting at 7:00 AM ET. The company specializes in implantable continuous glucose monitoring (CGM) systems, aimed at enhancing diabetes management. Their products include Eversense®, Eversense® XL, and Eversense® E3, which transmit glucose data to smartphones every five minutes.
Senseonics Holdings, Inc. (SENS) reported Q1 2022 financial results, showcasing total revenue of $2.5 million, a decrease from $2.8 million in Q1 2021. U.S. revenue rose to $0.8 million, while international revenue dropped to $1.7 million. The net income for Q1 2022 was reported at $86.7 million, significantly higher than the net loss of $249.5 million in Q1 2021, primarily due to adjustments in embedded derivatives. The gross profit remained stable at $0.5 million, though expenses increased due to R&D and operational costs. The company anticipates full-year 2022 net revenue between $14 million and $18 million.
Senseonics Holdings, Inc. (SENS) plans to release its first quarter 2022 financial results after market close on May 10, 2022. A conference call to discuss its performance will start at 4:30 p.m. ET on the same day, accessible via a dedicated webcast on their website. Senseonics focuses on developing long-term, implantable continuous glucose monitoring (CGM) systems for diabetes management, with products like Eversense® and Eversense® E3, which automatically send glucose data to smartphones every 5 minutes.
Senseonics Holdings, Inc. (AMEX: SENS) has announced the successful implantation of the first patient with the Eversense® E3 Continuous Glucose Monitoring (CGM) System in the U.S. This system, which received FDA approval in February, offers a 6-month sensor life, making it the longest-lasting CGM available. It features exceptional accuracy with a mean absolute relative difference (MARD) of 8.5%, reduced calibration frequency, and discreet on-body alerts. The Eversense E3 marks a significant advancement in diabetes care, enabling patients to manage their condition with improved confidence and convenience.
FAQ
What is the current stock price of Senseonics Holdings (SENS)?
What is the market cap of Senseonics Holdings (SENS)?
What does Senseonics Holdings, Inc. specialize in?
What is the Eversense Continuous Glucose Monitoring (CGM) System?
How long can the Eversense CGM System monitor glucose levels?
What is the Eversense Payment Assistance and Simple Savings (PASS) Program?
How does Senseonics' CGM technology benefit people with diabetes?
Where is Senseonics Holdings, Inc. headquartered?
Who are Senseonics' key partners?
How can I learn more about the Eversense CGM System?
Is the Eversense CGM System available outside the United States?
What is the mission of Senseonics Holdings, Inc.?
